Stock listing

Frankfurt:ROP Roper Technologies, Inc. Aktie

German listing (Frankfurt) of Roper Technologies, Inc. · home listing NASDAQ:ROP

Follow Roper Technologies, Inc. into a list and get an email when it puts out news.

Share price · FWB:ROP

€410.50 EUR +27.80 (+7.3%)

Close on Oct 30, 2026

Day range
€402.00 – €410.50 EUROct 30, 2026
Volume
35 sharesOct 30, 2026
Market cap
€40.60B EURAt the close on Oct 30, 2026 · price × 98.90M shares outstanding
Roper Technologies, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:ROP · Home$466.60 USD+16.95 (+3.8%)1,950,395$462.31$469.38$461.08$449.65Close on Oct 30, 2026
LSE:0KXM$435.01 USD-1.59 (-0.4%)180$442.47$453.09$429.70$436.60Close on Oct 27, 2026
Frankfurt:ROP€410.50 EUR+27.80 (+7.3%)35€402.00€410.50€402.00€382.70Close on Oct 30, 2026
B3:R1OP34218.90 BRL-1.70 (-0.8%)2218.90218.90218.90220.60Close on Oct 23, 2026
Stuttgart:ROP€391.10 EUR+4.10 (+1.1%)12€386.90€391.90€384.00€387.00Close on Oct 23, 2026
Ticker
Frankfurt:ROP
Asset type
Stock
Sector
Technology
Industry
Software
Exchange
Frankfurt
Currency
EUR

What changed lately

Calls

Replays

  • Roper Technologies (NASDAQ:ROP) Q3 2026 Earnings Call

    Thu, Oct 22, 2026 · 8:00 AM ET

    Watch Transcript

  • Roper Technologies (NASDAQ:ROP) Q2 2026 Earnings Call

    Thu, Jul 23, 2026 · 8:00 AM ET

    Watch Transcript

  • Roper Technologies (NASDAQ:ROP) Q1 2026 Earnings Call

    Thu, Apr 23, 2026 · 8:00 AM ET

    Watch Transcript

Latest news

Genentech’s Divarasib Demonstrated Best-in-Class Efficacy, Advancing the Standard of Care in Previously Treated KRAS G12C-mutated Lung Cancer

Oct 25, 2026

Genentech Presents Interim Phase III Data Showing Sefaxersen Significantly Reduced Proteinuria in People With IgA Nephropathy (IgAN)

Oct 23, 2026

Roper Technologies Announces Third Quarter Financial Results

Oct 22, 2026

Illumia and HID Strengthen Partnership to Simplify Campus Mobile Credential Adoption

Oct 21, 2026

Genentech Presents New Pivotal Trial Data Across Broad Neuroimmunology Portfolio at MSToronto2026

Oct 21, 2026

Genentech to Present Pivotal Data at ESMO 2026, Showcasing Advances Across Its Lung and Breast Cancer Late-Stage Portfolio

Oct 19, 2026

FDA Approves Genentech’s Enspryng, a First-in-Class IL-6R Inhibitor, as the First and Only At-Home Subcutaneous Treatment Option for Thyroid Eye Disease (TED)

Oct 16, 2026

Genentech Presents New Phase III One-Year Data for Vamikibart in Uveitic Macular Edema (UME), a Serious Cause of Vision Loss

Oct 10, 2026

Abhijit Dubey joins Roper Technologies Board of Directors

Oct 1, 2026

Roper Technologies schedules third quarter 2026 financial results conference call

Oct 1, 2026

All Roper Technologies, Inc. news

Decks

Roper Technologies, Inc. on 6ix

Sector
Technology
Industry
Software
News releases
34 in the last 12 months · 168 in all · newest Oct 25, 2026 · oldest 2019
Calls
27 calls with a replay · 27 with a transcript · latest Oct 22, 2026
Decks
47 decks · latest Oct 22, 2026

Where Roper Technologies, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:ROP · Home listingNASDAQUnited StatesUSD
Tradegate:ROPTradegateGermanyEUR
gettex:ROPgettexGermanyEUR
LS Exchange:883563LS ExchangeGermanyEUR
Lang & Schwarz:883563Lang & SchwarzGermanyEUR
LSE:0KXMLSEUnited KingdomUSD
Milan:1ROPMilanItalyEUR
Frankfurt:ROP · This pageFrankfurtGermanyEUR
B3:R1OP34B3BrazilBRL
BMV:ROPBMVMexicoMXN
BX Swiss:ROPCHFBX SwissSwitzerlandCHF
BOATS:ROPBOATSUnited StatesUSD
Dusseldorf:ROPDusseldorfGermanyEUR
Hanover:ROPHanoverGermanyEUR
BIVA:ROPBIVAMexicoMXN
BX Swiss:ROPUSDBX SwissSwitzerlandUSD
Stuttgart:ROPStuttgartGermanyEUR
Munich:ROPMunichGermanyEUR
Hamburg:ROPHamburgGermanyEUR
VIE:ROPViennaAustriaEUR
Xetra:ROPXetraGermanyEUR

Log in to ask 6ix AI your own questions about Roper Technologies, Inc.